Affiliation:
1. Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, China
2. Department of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, China
Abstract
Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative voiding, sexual dysfunction,
and pelvic pain. Chronic prostatitis/chronic pelvic pain syndrome weakens the quality of life and poses
adverse psychological effects on the patients. A wide range of treatments, including botulinum neurotoxins,
anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phosphodiesterase type 4 inhibitor,
phosphodiesterase type 5 inhibitor, monoclonal antibody, anticholinergics, gabapentin, pregabalin is used clinically.
These therapies emphasize easing the symptoms in specific areas without curing the fundamental cause
where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological
treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective
to treat this condition.
Funder
National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献